Phase II study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE (R)) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC)
dc.contributor.author | Ramalingam, S. S. | |
dc.contributor.author | Ahn, M. J. | |
dc.contributor.author | Akamatsu, H. | |
dc.contributor.author | Blackhall, Fiona H | |
dc.contributor.author | Borghaei, H. | |
dc.contributor.author | Hummel, H. D. | |
dc.contributor.author | Johnson, M. | |
dc.contributor.author | Reck, M. | |
dc.contributor.author | Zhang, Y. | |
dc.contributor.author | Jandial, D. | |
dc.contributor.author | Cheng, S. | |
dc.contributor.author | Paz-Ares, L. | |
dc.date.accessioned | 2022-04-28T13:57:38Z | |
dc.date.available | 2022-04-28T13:57:38Z | |
dc.date.issued | 2022 | en |
dc.identifier.citation | Ramalingam SS, Ahn MJ, Akamatsu H, Blackhall F, Borghaei H, Hummel HD, et al. Phase II study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE (R)) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC). Annals of Oncology. 2022;33:S103-S4. | en |
dc.identifier.doi | 10.1016/j.annonc.2022.02.186 | en |
dc.identifier.uri | http://hdl.handle.net/10541/625145 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1016/j.annonc.2022.02.186 | en |
dc.title | Phase II study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE (R)) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC) | en |
dc.type | Meetings and Proceedings | en |
dc.identifier.journal | Annals of Oncology | en |
dc.description.note | en] | |
refterms.dateFOA | 2022-06-28T09:45:06Z |